UA84903C2 - Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием - Google Patents

Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием

Info

Publication number
UA84903C2
UA84903C2 UAA200608870A UAA200608870A UA84903C2 UA 84903 C2 UA84903 C2 UA 84903C2 UA A200608870 A UAA200608870 A UA A200608870A UA A200608870 A UAA200608870 A UA A200608870A UA 84903 C2 UA84903 C2 UA 84903C2
Authority
UA
Ukraine
Prior art keywords
cci
directly compressible
pharmaceutical compositions
oral use
compressible pharmaceutical
Prior art date
Application number
UAA200608870A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мухаммад Ашраф
Эрик Дж. Бенджамин
Original Assignee
Уайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайет filed Critical Уайет
Publication of UA84903C2 publication Critical patent/UA84903C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к фармацевтике, в частности к фармацевтической композиции, которая содержит тонкоизмельченный ССІ-779. Изобретение касается также применения тонкоизмельченного ССІ-779 для получения лекарственного средства и пероральной ССІ-779 лекарственной единицы.
UAA200608870A 2004-01-08 2004-12-14 Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием UA84903C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
UA84903C2 true UA84903C2 (ru) 2008-12-10

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608870A UA84903C2 (ru) 2004-01-08 2004-12-14 Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием

Country Status (30)

Country Link
US (1) US20050152983A1 (ru)
EP (1) EP1701698B1 (ru)
JP (1) JP2007517879A (ru)
KR (1) KR20060130162A (ru)
CN (1) CN1921861A (ru)
AR (1) AR047180A1 (ru)
AT (1) ATE383859T1 (ru)
AU (1) AU2004314213A1 (ru)
BR (1) BRPI0418373A (ru)
CA (1) CA2552595A1 (ru)
CR (1) CR8491A (ru)
CY (1) CY1107373T1 (ru)
DE (1) DE602004011398T2 (ru)
DK (1) DK1701698T3 (ru)
EC (1) ECSP066757A (ru)
ES (1) ES2298861T3 (ru)
GT (1) GT200500003A (ru)
HN (1) HN2005000005A (ru)
IL (1) IL176519A0 (ru)
MX (1) MXPA06007829A (ru)
NO (1) NO20062930L (ru)
PA (1) PA8621201A1 (ru)
PE (1) PE20050683A1 (ru)
PL (1) PL1701698T3 (ru)
PT (1) PT1701698E (ru)
RU (1) RU2006122517A (ru)
TW (1) TW200526213A (ru)
UA (1) UA84903C2 (ru)
WO (1) WO2005070393A2 (ru)
ZA (1) ZA200605631B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2345999C2 (ru) 2003-09-03 2009-02-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
CA2562164A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
JP5475443B2 (ja) * 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2017038925A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
UA83484C2 (ru) * 2003-03-05 2008-07-25 Уайт Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru) * 2003-09-03 2009-02-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
GT200500003A (es) 2005-08-18
ES2298861T3 (es) 2008-05-16
PA8621201A1 (es) 2005-12-23
ZA200605631B (en) 2010-01-27
KR20060130162A (ko) 2006-12-18
AR047180A1 (es) 2006-01-11
PT1701698E (pt) 2008-03-27
MXPA06007829A (es) 2006-09-01
RU2006122517A (ru) 2008-02-20
PE20050683A1 (es) 2005-11-04
HN2005000005A (es) 2009-04-17
AU2004314213A1 (en) 2005-08-04
PL1701698T3 (pl) 2008-03-31
CR8491A (es) 2008-08-21
CN1921861A (zh) 2007-02-28
NO20062930L (no) 2006-10-02
ECSP066757A (es) 2006-11-16
DE602004011398D1 (de) 2008-03-06
WO2005070393A2 (en) 2005-08-04
DK1701698T3 (da) 2008-05-05
US20050152983A1 (en) 2005-07-14
EP1701698B1 (en) 2008-01-16
HK1090308A1 (en) 2006-12-22
WO2005070393A3 (en) 2006-09-28
DE602004011398T2 (de) 2009-01-15
CA2552595A1 (en) 2005-08-04
TW200526213A (en) 2005-08-16
CY1107373T1 (el) 2012-12-19
ATE383859T1 (de) 2008-02-15
BRPI0418373A (pt) 2007-05-22
EP1701698A2 (en) 2006-09-20
JP2007517879A (ja) 2007-07-05
IL176519A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
UA84903C2 (ru) Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ES2729679T3 (es) Derivados de morfinano para el tratamiento de la sobredosis de fármacos
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
SI1485094T2 (sl) Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NO20022442L (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
RU2011119643A (ru) Фармацевтические композиции с уменьшенным высвобождением фенольных опиоидов
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
TW200621249A (en) Substituted amide beta secretase inhibitors
IL149243A0 (en) Tetrapeptide-l-alanyl-l-glutamyl-l-aspartyl-l-proline and its salts and pharmaceutical compositions containing the same
TW200612909A (en) Compounds
WO2008030752A3 (en) Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
TW200603816A (en) Risedronate compositions and their methods of use
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EP2392322A3 (en) Dosing regimes for trans-clomiphene
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine